Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial

The Lancet

Volumn 386, Issue 9990, 2015, Pages 249-257

  Kehoe, Sean ^a   Hook, Jane ^b   Nankivell, Matthew ^b   Jayson, Gordon C ^c   Kitchener, Henry ^c   Lopes, Tito ^d   Luesley, David ^e   Perren, Timothy ^f   Bannoo, Selina ^b   Mascarenhas, Monica ^b   Dobbs, Stephen ^g   Essapen, Sharadah ^h   Twigg, Jeremy ⁱ   Herod, Jonathan ^j   McCluggage, Glenn ^k   Parmar, Mahesh ^b   Swart, Ann Marie ^b,l  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g BELFAST CITY HOSPITAL   (United Kingdom)

^h ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

ⁱ JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^j LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^k ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^l UNIVERSITY OF EAST ANGLIA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; CYSTOVAGINAL FISTULA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL PAIN; HUMAN; HYPOTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; INTESTINE FISTULA; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM FISTULA; SEPSIS; SURVIVAL RATE; TUMOR VOLUME; VAGINA DISEASE; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; OPERATION DURATION; OVARIAN NEOPLASMS; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OPERATIVE TIME; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84937636338     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62223-6     Document Type: Article

References (33)

1. Cancer Research UK Cancer stats report-ovarian cancer http://publications.cancerresearchuk.org/downloads/Product/CS-CS-OVARY.pdf March, 2011 (accessed July 3, 2014).
2. RE Bristow, RS Tomacruz, DK Armstrong, EL Trimble, FJ Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
3. A du Bois, A Reuss, E Pujade-Lauraine, P Harter, I Ray-Coquard, J Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
4. CT Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101 104
5. S Polterauer, I Vergote, N Concin et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data Int J Gynecol Cancer 22 2012 380 385
6. ME van der Burg, M van Lent, M Buyse et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med 332 1995 629 634
7. WE Winter 3rd, GL Maxwell, C Tian et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627
8. WE Winter 3rd, GL Maxwell, C Tian et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 26 2008 83 89
9. A du Bois, J Rochon, J Pfisterer, WJ Hoskins Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review Gynecol Oncol 112 2009 422 436
10. EJ Junor, DJ Hole, L McNulty, M Mason, J Young Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients Br J Obstet Gynaecol 106 1999 1130 1136
11. C Trope, J Kaern Primary surgery for ovarian cancer Eur J Surg Oncol 32 2006 844 852
12. JY Hou, MG Kelly, H Yu et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 2007 211 217
13. I Vergote, I De Wever, W Tjalma, M Van Gramberen, J Decloedt, P van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
14. RE Bristow, DS Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076
15. S Kang, BH Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
16. JL Benedet, H Bender, H Jones 3rd, HY Ngan, S Pecorelli FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 2000 209 262
17. CA Yedema, P Kenemans, T Wobbes et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas Tumour Biol 13 1992 18 26
18. WHO WHO handbook for reporting results of cancer treatment. WHO Offset Publication 48th edn. 1979 World Health Organization Geneva
19. I Vergote, GJ Rustin, EA Eisenhauer et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534 1535
20. PM Fayers Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30 Eur J Cancer 37 2001 1331 1334
21. I Vergote, CG Trope, F Amant et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
22. S Kehoe, J Hook, M Nankivell et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial J Clin Oncol 31 2013 abstr 5500.
23. PM Grambsch, TM Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 1994 515 526
24. D Osoba, G Rodrigues, J Myles, B Zee, J Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
25. P Fayers, NK Aaronson, K Bjordal, D Curran, M Groenvold EORTC QLQ-C30 scoring manual 3rd edn. 2001 EORTC Quality of Life Group Brussels 86
26. MKB Parmar, V Torri, L Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
27. S Pignata, G Scambia, D Katsaros et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol 15 2014 396 405
28. TJ Perren, AM Swart, J Pfisterer et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
29. PG Rose, S Nerenstone, MF Brady et al. Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
30. C Ang, KK Chan, A Bryant et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer Cochrane Database Syst Rev 13 2011 CD007697.
31. CG Gerestein, RA Damhuis, CW Burger, GS Kooi Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review Gynecol Oncol 114 2009 523 527
32. MM Thrall, BA Goff, RG Symons, DR Flum, HJ Gray Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly Obstet Gynecol 118 2011 537 547
33. National Institute of Clinical Excellence Guidance on the use of paclitaxel in the treatment of ovarian cancer. Issued January, 2003, modified May, 2005 https://www.nice.org.uk/guidance/ta55 (accessed July 3, 2014).